Altimmune, Inc. (ALT)
Largest Insider Buys in Sector
ALT Stock Price History Chart
ALT Stock Performance
About Altimmune, Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known …
Insider Activity of Altimmune, Inc.
Over the last 12 months, insiders at Altimmune, Inc. have bought $0 and sold $110,547 worth of Altimmune, Inc. stock.
On average, over the past 5 years, insiders at Altimmune, Inc. have bought $5.72M and sold $718,037 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 300 shares for transaction amount of $863 was made by Drutz David (director) on 2023‑08‑15.
List of Insider Buy and Sell Transactions, Altimmune, Inc.
| 2024-08-19 | Sale | director | 16,011 0.0206% | $6.90 | $110,547 | -10.61% | ||
| 2023-08-15 | director | 300 0.0006% | $2.88 | $863 | +149.13% | |||
| 2023-03-24 | Chief Financial Officer | 10,000 0.0213% | $4.31 | $43,140 | -5.32% | |||
| 2023-03-23 | Chief Medical Officer | 10,000 0.0215% | $4.22 | $42,200 | -2.39% | |||
| 2023-03-23 | director | 9,000 0.0195% | $4.27 | $38,430 | -2.39% | |||
| 2022-12-22 | Sale | director | 20,000 0.0383% | $15.01 | $300,268 | -73.88% | ||
| 2022-08-30 | Sale | President and CEO | 20,000 0.0429% | $20.02 | $400,322 | -47.31% | ||
| 2022-08-12 | Sale | President and CEO | 15,000 0.0264% | $15.06 | $225,890 | -39.75% | ||
| 2022-08-12 | Sale | director | 2,714 0.0048% | $15.00 | $40,710 | -39.75% | ||
| 2022-07-01 | Sale | Chief Scientific Officer | 10,182 0.022% | $12.00 | $122,184 | +0.62% | ||
| 2022-06-29 | Sale | Chief Scientific Officer | 5,462 0.0117% | $12.00 | $65,546 | -3.74% | ||
| 2022-06-27 | Sale | Chief Scientific Officer | 37,352 0.0803% | $12.00 | $448,254 | -3.40% | ||
| 2022-06-27 | Sale | 17,610 0.0371% | $11.75 | $206,944 | -3.40% | |||
| 2022-06-15 | 1,000 0.002% | $8.00 | $8,000 | +36.66% | ||||
| 2022-05-24 | 1,200 0.0024% | $4.50 | $5,400 | +140.89% | ||||
| 2022-02-28 | Sale | Chief Medical Officer | 30,000 0.0692% | $7.52 | $225,600 | +52.50% | ||
| 2021-03-01 | Sale | director | 6,000 0.0151% | $16.08 | $96,480 | -28.09% | ||
| 2020-12-10 | director | 2,000 0.0076% | $11.99 | $23,980 | +5.50% | |||
| 2020-12-01 | Sale | director | 1,227 0.0047% | $13.54 | $16,614 | -6.30% | ||
| 2020-11-30 | Sale | director | 2,500 0.0096% | $12.00 | $30,000 | +6.26% |
Insider Historical Profitability
| Drutz David | director | 41958 0.059% | $7.25 | 6 | 1 | +23.34% |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10 percent owner | 6626403 9.3237% | $7.25 | 1 | 3 | <0.0001% |
| EVNIN LUKE | 10 percent owner | 6347614 8.9314% | $7.25 | 2 | 0 | |
| MPM BIOVENTURES III LLC | 10 percent owner | 6347614 8.9314% | $7.25 | 2 | 0 | |
| Venrock Healthcare Capital Partners III, L.P. | 10 percent owner | 4500000 6.3317% | $7.25 | 4 | 0 | +64.5% |
Institutional Investor Ownership
| State Street | $88.05M | 12.2 | 8.65M | +752.53% | +$77.72M | <0.01 | |
| BlackRock | $41.15M | 5.7 | 4.04M | -0.06% | -$25,256.58 | <0.01 | |
| The Vanguard Group | $31.85M | 4.41 | 3.13M | -12.41% | -$4.51M | <0.01 | |
| Tang Capital Management, LLC | $28M | 3.88 | 2.75M | 0% | +$0 | 0.11 | |
| Morgan Stanley | $22.52M | 3.12 | 2.21M | +112.5% | +$11.92M | <0.01 |